210 related articles for article (PubMed ID: 32276795)
41. Seroprevalence of hepatitis C virus and associated risk behaviours: a population-based study in San Juan, Puerto Rico.
Pérez CM; Suárez E; Torres EA; Román K; Colón V
Int J Epidemiol; 2005 Jun; 34(3):593-9. PubMed ID: 15802378
[TBL] [Abstract][Full Text] [Related]
42. High-risk drug-use practices among a large sample of Australian prisoners.
Kinner SA; Jenkinson R; Gouillou M; Milloy MJ
Drug Alcohol Depend; 2012 Nov; 126(1-2):156-60. PubMed ID: 22658284
[TBL] [Abstract][Full Text] [Related]
43. Drug abuse of Finnish male prisoners in 1995.
Korte T; Pykäläinen J; Seppälä T
Forensic Sci Int; 1998 Nov; 97(2-3):171-83. PubMed ID: 9871996
[TBL] [Abstract][Full Text] [Related]
44. HIV testing among incarcerated people with a history of HIV-related high-risk behaviours in Iran: Findings from three consecutive national bio-behavioural surveys.
Tavakoli F; Parhizgari N; Shokoohi M; Khezri M; Haghdoost AA; Ghasemzadeh I; Bozicevic I; Shahesmaeili A; Nasiri N; Danesh A; Karamouzian M; Sharifi H
BMC Infect Dis; 2022 Dec; 22(1):907. PubMed ID: 36471282
[TBL] [Abstract][Full Text] [Related]
45. Injecting Drug Users Retention in Needle-Exchange Program and its Determinants in Iran Prisons.
Shahbazi M; Farnia M; Moradi G; Karamati M; Paknazar F; Mirmohammad Khani M
Int J High Risk Behav Addict; 2015 Jun; 4(2):e23751. PubMed ID: 26405681
[TBL] [Abstract][Full Text] [Related]
46. Prevalence of Hepatitis B and C among Drug-Abusing Male Prisoners in Birjand, South Khorasan, Iran.
Ghafari S; Sharifzadeh G; Jamali S; Taji B; Javadmoosavi SY; Ziaee M
Arch Iran Med; 2019 Sep; 22(9):501-504. PubMed ID: 31679371
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of antibodies to human immunodeficiency virus (HIV), hepatitis B and hepatitis C and risk factors in prisoners in Lebanon.
Mahfoud Z; Kassak K; Kreidieh K; Shamra S; Ramia S
J Infect Dev Ctries; 2010 Mar; 4(3):144-9. PubMed ID: 20351454
[TBL] [Abstract][Full Text] [Related]
48. The role of prisons in the HIV epidemic among female injecting drug users.
Estébanez P; Zunzunegui MV; Aguilar MD; Russell N; Cifuentes I; Hankins C
AIDS Care; 2002 Feb; 14(1):95-104. PubMed ID: 11798408
[TBL] [Abstract][Full Text] [Related]
49. Substance use among inmates at the Eldoret prison in Western Kenya.
Kinyanjui DW; Atwoli L
BMC Psychiatry; 2013 Feb; 13():53. PubMed ID: 23406288
[TBL] [Abstract][Full Text] [Related]
50. Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico.
Belaunzarán-Zamudio PF; Mosqueda-Gomez JL; Macias-Hernandez A; Sierra-Madero JG; Ahmed S; Beyrer C
PLoS One; 2017; 12(6):e0179931. PubMed ID: 28654650
[TBL] [Abstract][Full Text] [Related]
51. Factors associated with psychoactive substance use among a sample of prison inmates in Ilesa, Nigeria.
Amdzaranda PA; Fatoye FO; Oyebanji AO; Ogunro AS; Fatoye GK
Niger Postgrad Med J; 2009 Jun; 16(2):109-14. PubMed ID: 19606190
[TBL] [Abstract][Full Text] [Related]
52. HCV seropositivity in inmates and in the general population: an averaging approach to establish priority prevention interventions.
Roux P; Sagaon-Teyssier L; Lions C; Fugon L; Verger P; Carrieri MP
BMJ Open; 2014 Oct; 4(10):e005694. PubMed ID: 25331969
[TBL] [Abstract][Full Text] [Related]
53. Tattooing: A national survey in the general population of France.
Kluger N; Misery L; Seité S; Taieb C
J Am Acad Dermatol; 2019 Aug; 81(2):607-610. PubMed ID: 30395921
[No Abstract] [Full Text] [Related]
54. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: a national cross sectional survey.
Long J; Allwright S; Barry J; Reynolds SR; Thornton L; Bradley F; Parry JV
BMJ; 2001 Nov; 323(7323):1209-13. PubMed ID: 11719410
[TBL] [Abstract][Full Text] [Related]
55. Prevalence and appropriateness of psychotropic medication prescribing in a nationally representative cross-sectional survey of male and female prisoners in England.
Hassan L; Senior J; Webb RT; Frisher M; Tully MP; While D; Shaw JJ
BMC Psychiatry; 2016 Oct; 16(1):346. PubMed ID: 27724879
[TBL] [Abstract][Full Text] [Related]
56. Prisoners should not be left behind in HCV research and policies.
Moazen B; Stöver H; Dolan K; Jahn A; Neuhann F
Harm Reduct J; 2020 May; 17(1):33. PubMed ID: 32448290
[TBL] [Abstract][Full Text] [Related]
57. Drug use prior to incarceration and associated socio-behavioural factors among males in a provincial correctional facility in Ontario, Canada.
Kouyoumdjian FG; Calzavara LM; Kiefer L; Main C; Bondy SJ
Can J Public Health; 2014 May; 105(3):e198-202. PubMed ID: 25165839
[TBL] [Abstract][Full Text] [Related]
58. Comparison of social circumstances, substance use and substance-related harm in soon-to-be-released prisoners with and without intellectual disability.
Bhandari A; van Dooren K; Eastgate G; Lennox N; Kinner SA
J Intellect Disabil Res; 2015 Jun; 59(6):571-9. PubMed ID: 25171498
[TBL] [Abstract][Full Text] [Related]
59. Burden of HIV, Syphilis, and Hepatitis B and C Among Inmates in a Prison State System in Mexico.
Belaunzaran-Zamudio PF; Mosqueda-Gomez JL; Macias-Hernandez A; Rodríguez-Ramírez S; Sierra-Madero J; Beyrer C
AIDS Res Hum Retroviruses; 2017 Jun; 33(6):524-533. PubMed ID: 28094553
[TBL] [Abstract][Full Text] [Related]
60. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries.
Bielen R; Stumo SR; Halford R; Werling K; Reic T; Stöver H; Robaeys G; Lazarus JV
Harm Reduct J; 2018 May; 15(1):25. PubMed ID: 29751763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
